---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-25-000104"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:08:15.859752+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q3 net loss $31M vs income $106M YoY; revenue +4% to $776M; guidance raised

## Summary
- GAAP net loss of $31M (diluted EPS -$0.16) vs income $106M ($0.55) in Q3 2024, due to $221M IPR&D charge from Inozyme acquisition.
- Non-GAAP income fell to $22M ($0.12 EPS) from $178M ($0.91), reflecting the Inozyme charge and SG&A investments.
- Total revenue $776M (+4% YoY); VOXZOGO $218M (+15%), PALYNZIQ $109M (+20%), but ALDURAZYME -24% and NAGLAZYME -8%.
- Full-year 2025 total revenue guidance raised at midpoint; VOXZOGO outlook reaffirmed at $900M-$935M.
- Company pursuing options to divest ROCTAVIAN (hemophilia A gene therapy), including out-licensing.

## SEC filing metadata
- accession: 0001048477-25-000104
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/0001048477-25-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/bmrn-20251027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-25-000104
- JSON: https://secwatch.observer/filing/0001048477-25-000104.json
- Plain text: https://secwatch.observer/filing/0001048477-25-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.